CFO exercised or converted 20K MRNA derivative securities | OQRO Insider tradesWhy it stands out
Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Sep 10, 2026
- Reporting period
- Not applicable
- Filed with the SEC
- Sep 14, 2026
CFOOption exercise
Context
- Classification
option exercise
Code M — exercise or conversion of a derivative security
- Planned / mechanical clue
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0001682852-26-000174
Added to OQROOct 2, 2026, 12:28 PM UTC Data qualityVerified: identifiers matched exactly Reporting personJames M Mock Officer titleChief Financial Officer TableNon-derivative (Table I) Transaction dateSep 10, 2026 Acquired / disposedAcquired (A) Footnotes from the filing
- The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026.
Around the same time
Derivative exercise or conversion — not an open-market buy.
Officer sold ~$5.81M of Moderna
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.